...
首页> 外文期刊>Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology >Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis.
【24h】

Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis.

机译:选择性Rho激酶抑制剂fasudil对实验性自身免疫性神经炎的预防和治疗作用。

获取原文
获取原文并翻译 | 示例
           

摘要

We studied the effects of fasudil, a selective Rho-kinase inhibitor, on experimental autoimmune neuritis (EAN). Continuous parenteral administration of fasudil prevented the development of EAN induced by P0 peptide 180-199 in Lewis rats while it also reduced EAN severity when administered after disease onset. Immunohistochemical examination disclosed a marked decrease in the amount of inflammatory cell infiltration and attenuation of demyelination and axonal degeneration. Specific proliferation of lymphocytes from fasudil-treated rats in response to P0 peptide was significantly reduced as compared with those from phosphate-buffered saline (PBS)-treated rats. Fasudil treatment was associated with a significant reduction in secretion of IFN-gamma; by contrast, secretion of IL-4 was almost the same in the fasudil- and PBS-treated groups. As a result, the IFN-gamma/IL-4 ratio in the supernatant was significantly deceased in fasudil-treated rats compared with PBS-treated ones. Therefore, our results indicate a beneficial effect of selective blockade of Rho-kinase in animals with autoimmune inflammation of the peripheral nerves, and may provide a rationale for the selective blockade of Rho-kinase as a new therapy for Guillain-Barre syndrome.
机译:我们研究了选择性Rho激酶抑制剂法舒地尔对实验性自身免疫性神经炎(EAN)的影响。连续胃肠外给药法舒地尔可预防Lewis大鼠中P0肽180-199诱导的EAN的发展,同时也可在疾病发作后降低EAN的严重程度。免疫组织化学检查显示炎性细胞浸润量显着减少,脱髓鞘和轴突变性减弱。与磷酸盐缓冲液(PBS)处理的大鼠相比,接受法舒地尔处理的大鼠的淋巴细胞对P0肽的特异性增殖显着降低。法舒地尔治疗与IFN-γ的分泌显着减少有关。相比之下,法舒地尔和PBS处理组的IL-4分泌几乎相同。结果,与经PBS处理的大鼠相比,经法舒地尔处理的大鼠的上清液中的IFN-γ/ IL-4比率显着降低。因此,我们的结果表明选择性阻断Rho激酶对周围神经具有自身免疫性炎症的动物具有有益作用,并且可能为选择性阻断Rho激酶提供了一种作为格林巴利综合征新疗法的理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号